Published in Obesity and Diabetes Week, January 1st, 2007
Janumet is designed to provide an additional treatment option for patients who need more than one oral agent to help control their blood sugar and is currently under standard review by the U.S. Food and Drug Administration (FDA). Merck expects FDA action on the new drug application (NDA) by the end of March 2007. The company is also moving forward as planned with regulatory filings in countries outside the United States.
Data supporting Janumet previously reported at the 66th...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week